In This Issue, Volume 8, Issue 6

Bruton’s tyrosine kinase (Btk) is central to the function of B cells and myeloid cells and thus presents a therapeutic target for immunological disorders and B-cell lymphomas. Development of Btk inhibitors is actively ongoing within the pharmaceutical community, and one compound, ibrutinib, was recently approved for the treatment of certain types of cancers. However, approved Btk inhibitors for nononcology applications are lacking